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Abstract
BACKGROUND: Prostate cancer is a major health concern of men. Vitamin D can modulate innate or adaptive 
immune responses. The anticancer and anti-inflammatory effects of Vitamin D are mediated through gene 
transcription by Vitamin D receptor (VDR), including angiogenesis and tumor cell invasion. Targeted therapy in 
carcinoma prostate such as is as calcitriol is an alternative therapy for better treatment outcome. 
METHODS AND MATERIALS: We investigated VDR immunoexpression in benign prostatic hyperplasia (BPH) 
and prostate adenocarcinoma. The cross-sectional study, categorical analysis of 60 paraffin blocks consist of 
30 samples diagnosed as BPH, and 30 samples of prostate adenocarcinoma were divided three grading groups 
based on Patterns of Gleason: low, moderate, and high grade. Immunostaining was used to evaluate the VDR 
immunoexpression by histoscore. 
RESULTS: The results showed that strong expression of VDR was 40% in BPH and 33.33% in prostate 
adenocarcinoma (p = 0.961). The strong expression of VDR in low, moderate, and high grade was 10%, 3.33%, and 
20%, respectively. Statistically, there is no significant different (p = 0.906). 
CONCLUSION: Positive immunoexpression of VDR affected the differentiation of prostatic adenocarcinoma.
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Introduction
Prostate cancer (Pca) is the second common 
malignancy of men in the world and is the fifth leading 
cause of death, an estimated 307,000 deaths in 2012 [1]. 
In the United States, Pca mortality rates are increasing; 
in 2013, it was estimated 29,720 men died and in 2014, 
there will be an estimated 585,720 cancer deaths [2]. 
Physiologically, men who have age more than 50 years 
old usually occurred enlargement of the prostate, but 
not all prostate enlargement is Pca. Screening should 
be done by ultrasonography and prostatic specific 
antigen examination to determine whether the condition 
is benign prostatic hyperplasia (BPH) or Pca [3].
Recently, the role of calcitriol as a target 
therapy for cancer is often discussed. Target therapy is 
a specific therapy to inhibit factors that are considered 
as a cause of carsinogenesis process. Calcitriol is the 
most active of metabolite Vitamin D [4]. Calcitriol in vitro 
and in vivo experiments indicated synergistically with 
chemotherapy agents. Vitamin D is one of the hormones 
associated with a lower risk of several types of cancer, 
including Pca [5].
The prostate gland is an organ that has 
Vitamin D receptors (VDR) and responds to 1.25 (OH) 2D. 
In addition, these tissues and cells express the enzyme 
25-hydroxyvitamin D-1-hydroxylase which converts 25 
(OH) D to 1.25 (OH) 2D. The active form of Vitamin D 
has been shown to have a strong cell regulation effect in 
cells besides also being involved in calcium homeostasis. 
These effects are mediated through VDR. The binding 
of VDR by 1.25 (OH) D causes several cellular effects, 
including induced differentiation and apoptosis and 
inhibited proliferation, angiogenesis, and metastatic 
potential. Thus, Vitamin D is believed to play an important 
role in the etiology and treatment of cancer [6], [7].
VDR expression can be over-expression or 
under-expression (suppressed) in various types of 
cancer. Over-expression of VDR indicates a large number 
of VDRs so that it can bind calcitriol. The identification 
of VDR in tumor tissue by immunohistochemical 
examination is a good method and is a modality for the 
development of target therapy [8]. Therefore, this study 
was conducted to the detected expression of VDR in 
BPH and prostate adenocarcinoma.
Methods
The sample was a paraffin block from patients 
diagnosed with BPH and prostate adenocarcinomas at 
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Grand Medistra Hospital, Lubuk Pakam, Medan. The 
inclusion criteria were cases diagnosed according to 
the WHO 2016 [9]. Exclusion criteria were damaged by 
paraffin blocks and samples that could not be daubed 
with hematoxylin-eosin and immunohistochemical VDR. 
Examination of immunohistochemical VDR is carried 
out at Anatomic Pathology Laboratory, Universitas 
Sumatera Utara.
This study consisted of two groups, namely, 
benign and malignant prostate, each with 30 samples. 
Thus, the malignant group divided three grades; low 
(grade 1 and 2), moderate (grade 3), and high (grade 
4 and 5) according to the WHO criteria. This study 
was a descriptive-analytic with a cross-sectional 
approach. Permission and approval were obtained from 
the Medical Ethics Committee Faculty of Medicine, 
Universitas Sumatera Utara.
The VDR immunoexpression is immunoreactive 
tumor cells against appearance immunohistochemicals 
that use antibodies VDR. The assessment of VDR 
expression is done by the observed intensity and 
immunohistochemical outward distribution. Primary 
antibodies used are mouse anti-human VDR (D-6) 
antibody monoclonal (Medaysis) with a dilution of 
1:500 in solution PBS. Intensity consists of negatives 
(score 0), weak (score 1), moderate (score 2), and 
strong (score 3). Distribution assessment is done 
with divide large field into four equal fields as a 25% 
distribution. Percentage of cells in all four fields then 
added and obtained into total VDR expression into 
one large field. The distribution level determined as 
0=negative, 1≤10%, 2=10-50% and 3=50%. Based on 
the intensity value and distribution of VDR, expressions 
can be calculated histoscore (Intensity × Distribution), 
that is, weak (1–3), moderate (4–6), and strong (7–9) 
[10], [11].
Results and Discussion
The sample used is a paraffin block of the 
60 patients included in this study (Table 1). The patient 
with age >70 years old more than age <70 years old. 
The mean age at diagnosis in this study was 69.2 years, 
and the youngest patient was 44 years. This is in line 
with studies done by Gurumurthy et al. and Jackson 
et al. [12], [13]. These findings confirm that Pca is a 
disease of elderly men, although young men are not 
excluded from the study.
Based on the results of immunoexpression, 
analysis showed positively strong VDR immunoexpression 
in BPH groups which were 12 cases (40%), whereas 
the adenocarcinoma groups were 10 cases (33.3%) 
(Table 2). Statistically, analysis showed not significant 
correlation p = 0.961.
Table 2: Results of VDR immunoexpression in benign and 
malignant prostate tumors
Immunoexpression of VDR BPH Prostate adenocarcinoma Total p
N (%) N (%) n (%)
Weak 5 16.7 5 16.7 10 16.7
Moderate 13 43.3 15 50 28 46.7 0.961
Strong 12 40 10 33.3 22 36.6
Total 30 100 30 100 60 100
BPH: Benign Prostatic Hyperplasia.
The results of immunoexpression VDR with the 
degree of differentiation of prostate adenocarcinoma are 
shown in Table 3. The data showed low-grade groups 
give results positively strong VDR immunoexpression 
of three cases (10%), whereas high grade was 6 cases 
(20%) with p = 0.906. Totally, results showed that 
in all groups (low, moderate, and high), expression 
VDR in positively moderate was higher than positively 
strong. This study comparable with studies done by 
Hendrickson et al. showed that protein expression 
of VDR was highest with Gleason 3+3 tumors and 
decreased with increasing pathologic Gleason score 
(p < 0.001) [5].
Table 3: Results of VDR immunoexpression in prostate 
adenocarcinoma
Immunoexpression 
of VDR
Prostate adenocarcinoma Total p
Low grade Moderate grade High grade
n % N % n % n %
Weak 1 3.3 0 0 4 13.3 5 16.7
Moderate 5 16.7 3 1 7 23.4 15 50 0.906
Strong 3 10 1 3.3 6 20 10 33.3
Total 9 30 4 4.3 17 56.7 30 100
VDR tumor staining was evident intracellular in 
the cytoplasm, membrane cell, and nuclear [14]. There 
was considerable variability in staining of VDR across 
the BPH and prostate adenocarcinoma (Figure 1). 
The mechanism of VDR affected differentiation can 
be through genomic pathways in the nucleus that 
is Vitamin D or, in its active form, calcitriol binds to 
VDR forming heterodimers with retinoic X receptors 
(RXR) and with its ligands (nine cisretinoic acids). The 
dimer is forming complex with Vitamin D response-
related elements with gene transcription to produce 
differentiation function [15], [16]. VDR also has 
nongenomic pathway that is in the cytoplasm with the 
mechanism of rapid action VDR binding to calcitriol on 
the VDR membrane in caveolae plasma membrane. 
Binding VDR with calcitriol on the plasma membrane 
activated several second messengers system.
The results of this study indicate that there is 
no correlation between VDR immunoexpression with 
benign and malignant prostate tumors. Expression VDR 
in positively moderate was higher than positively strong 
in benign and malignant prostate tumors, which may 
Table 1: Characteristic clinicopathology of sample
Variable n (%)
Age
Median 70
Range 69.2
Benign prostatic hyperplasia 30 (50)
Prostate adenocarcinoma 30 (50)
Low grade 9 (30)
Moderate grade 4 (4.3)
High grade 17 (56.7)
Total sample 60 (100)
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be another factor that influences; further, the study is 
needed. However, VDR correlates with the high-grade 
group may be the administration of Vitamin D target 
therapy or in its active form; calcitriol can be given to 
the high-grade group.
Conclusion
Positive immunoexpression of VDR affected 
the differentiation of benign and malignant prostate 
tumors.
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Figure 1: Overview of Vitamin D receptor immunoexpression. Strong 
intensity, cytoplasm (black arrow), and tumor cell membrane (blue 
arrow) dark brown shown in figure (a), while moderate-intensity, 
cytoplasm, and tumor cells are brown in color younger than the figure 
(a) is shown in figure (b). Weak intensity, cytoplasm, and tumor cell 
membrane light brown shown in figure (c). Image was taken 400× 
magnification
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